Table 1.
Clinical trial programmes of advanced therapies for the treatment of ulcerative colitis.
| Therapy | Clinical trial | ClinicalTrials.gov registration number | Years conducted |
|---|---|---|---|
| Infliximab5 | ACT 1 and ACT 2 [phase 3 induction and maintenance] | NCT00036439 and NCT00096655 | 2002–2005 |
| Adalimumab6,7 | ULTRA 1 [phase 3 induction], ULTRA 2 [phase 3 induction and maintenance] | NCT00385736, NCT00408629 | 2007–2010 2006–2010 |
| Golimumab8,9 | PURSUIT-SC [phase 2/3 induction], PURSUIT-M [phase 3 maintenance] | NCT00487539, NCT00488631 | 2007–2010 2007–2011 |
| Vedolizumab10,11 | GEMINI 1 [phase 3 induction], GEMINI 1 [phase 3 maintenance] | NCT00783718 | 2008–2012 |
| Tofacitinib18 | OCTAVE Induction 1 and OCTAVE Induction 2 [phase 3 induction], OCTAVE Sustain [phase 3 maintenance] | NCT01465763 and NCT01458951, NCT01458574 | 2012–2016 2012–2016 |
| Ozanimod19 | TOUCHSTONE [phase 2 induction and maintenance] | NCT01647516 | 2012–2015 |
| Etrolizumab20 | HICKORY [phase 3 induction and maintenance] | NCT02100696 | 2014–ongoing |